Boston Scientific Corporation $BSX Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue cut its stake in Boston Scientific Corporation (NYSE:BSX) by 4.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 158,433 shares of the medical equipment provider’s stock after selling 7,823 shares during the period. State of Alaska Department of Revenue’s holdings in Boston Scientific were worth $15,467,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FWL Investment Management LLC bought a new position in Boston Scientific during the 2nd quarter valued at $26,000. Sound Income Strategies LLC raised its stake in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 120 shares in the last quarter. Steph & Co. acquired a new stake in shares of Boston Scientific in the third quarter valued at $25,000. Financial Consulate Inc. bought a new position in Boston Scientific during the third quarter valued at about $25,000. Finally, Kilter Group LLC acquired a new position in Boston Scientific during the second quarter worth about $30,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $98.43 on Friday. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50. The business’s fifty day moving average is $97.64 and its two-hundred day moving average is $100.81. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The firm has a market cap of $145.92 billion, a P/E ratio of 52.64, a P/E/G ratio of 1.75 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm’s quarterly revenue was up 20.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Canaccord Genuity Group dropped their price target on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Robert W. Baird lifted their price target on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Leerink Partners boosted their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Needham & Company LLC restated a “buy” rating and set a $121.00 price target on shares of Boston Scientific in a report on Friday, October 17th. Finally, Erste Group Bank downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $124.35.

Insider Buying and Selling at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 93,095 shares of company stock valued at $9,305,450. Company insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.